Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 F590_D593delinsLY |
Therapy | Quizartinib |
Indication/Tumor Type | hematologic cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 F590_D593delinsLY | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) inhibited Flt3 and Stat5 phosphorylation and viability in cells expressing FLT3 F590_D593delinsLY in culture (PMID: 26012842). | 26012842 |
PubMed Id | Reference Title | Details |
---|---|---|
(26012842) | Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. | Full reference... |